Highlights Newsletter 4
This newsletter presents you the best read sessions:
1. Adjuvant avelumab does not significantly improve disease-free survival in high-risk TNBC patients
This newsletter presents you the best read sessions:
1. Adjuvant avelumab does not significantly improve disease-free survival in high-risk TNBC patients